Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Prelude Therapeutics Inc (PRLD) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update",
"Presentation"
06/01/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "D ENGINE DIFFERENTIATED PROGRAMS APPROACH CDK9 MCL1 SMARCA2 CDK4/6"
05/24/2023 SC 13D/A ORBIMED ADVISORS LLC reports a 28.6% stake in Prelude Therapeutics Incorporated
05/24/2023 SC 13D/A BAKER BROS. ADVISORS LP reports a 19.5% stake in Prelude Therapeutics Incorporated
05/19/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/19/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement",
"Form of Pre-Funded Warrant",
"Opinion of Fenwick & West LLP",
"Prelude Therapeutics Announces Launch of Proposed Public Offering",
"Prelude Therapeutics Announces Pricing of Public Offering"
05/18/2023 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
05/17/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/15/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Open Market Sale AgreementSM, by and between Prelude Therapeutics Incorporated and Jefferies LLC",
"Opinion of Fenwick & West LLP"
03/15/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/15/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/15/2023 10-K Annual Report for the period ended December 31, 2022
03/15/2023 8-K Quarterly results
Docs: "Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update Four differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Association for Cancer Research Annual Meeting Cash balance of $201.7 million as of December 31, 2022; runway remains unchanged through Q4 2024 Wilmington, DE – March 15, 2023 –",
"D ENGINE DIFFERENTIATED PROGRAMS APPROACH CDK9 MCL1 SMARCA2 CDK4/6",
"Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers WILMINGTON, Del. – March 15, 2023 –"
02/14/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "PRT543, PRT811, PRT1419, PRT2527, PRT3645, PRT3789"
02/13/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/10/2023 SC 13G/A FMR LLC reports a 10.2% stake in PRELUDE THERAPEUTICS INC
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A FMR LLC reports a 9.6% stake in PRELUDE THERAPEUTICS INC
01/23/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BYLAWS As Amended and Restated on January 19, 2023 PRELUDE THERAPEUTICS INCORPORATED AMENDED AND RESTATED BYLAWS"
01/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "PRT543, PRT811, PRT1419, PRT2527, PRT3645, PRT3789"
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 8-K Quarterly results
Docs: "Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update FDA clearance of two new INDs: PRT3789 and PRT3645 Company to reprioritize clinical pipeline and discontinue PRMT5 program for internal development Strong cash, cash equivalents and marketable securities of $224.0 million as of September 30, 2022, expected to fund multiple data catalysts with a runway into the fourth quarter of 2024 WILMINGTON, Del.",
"PRT543, PRT811, PRT1419, PRT2527, PRT3645, PRT3789"
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
05/10/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/10/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy